作者
Sebastien Taurin, Chieh-Hsiang Yang, Maria Reyes, Sungpil Cho, Demetrius M Coombs, Elke A Jarboe, Theresa L Werner, C Matthew Peterson, Margit M Janát-Amsbury
发表日期
2018/1/1
期刊
International Journal of Gynecologic Cancer
卷号
28
期号
1
出版商
BMJ Specialist Journals
简介
Objectives
AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFβ), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). This study evaluates the efficacy of AL3818 studying tumor regression in an orthotopic murine endometrial cancer model.
Methods
We tested the cytotoxicity of AL3818 on a panel of 7 human endometrial cancer cell lines expressing either wild-type or mutant FGFR2 and also assessed the in vivo antitumor efficacy in a murine, orthotopic AN3CA endometrial cancer model. AL3818 was administered daily per os either alone or in combination with carboplatin and paclitaxel, which represent the current standard of adjuvant care for endometrial cancer.
Results
AL3818 significantly reduces AN3CA cell number in vitro …
学术搜索中的文章
S Taurin, CH Yang, M Reyes, S Cho, DM Coombs… - International Journal of Gynecologic Cancer, 2018